New Stroke Prevention Pill: What Asundexian Changes

Your father had a small stroke in the spring. He recovered well, his speech came back, and he now takes a daily aspirin and a statin. Then his neurologist mentions a new stroke prevention pill that just won FDA approval, and asks whether he wants to add it.

That question is about to come up in a lot of follow-up appointments. On November 9, the FDA approved Bayer's Sunharbo (asundexian), the first drug in a new class called factor XIa inhibitors. The stakes are high. Anyone who has had one stroke carries a real risk of a second, and the pills that thin the blood harder have always carried a bleeding cost that limited how far doctors could push them.

This guide explains what the new pill does differently, what the main trial actually showed in plain numbers, who it is meant for, who it is not for, and the questions to bring to your doctor before you decide anything.

Why a Second Stroke Is the Risk Doctors Worry About

Stroke is common, and repeat strokes are a big slice of the total. According to the CDC's stroke statistics, more than 795,000 people in the US have a stroke each year. About 185,000 of those, nearly 1 in 4, happen to people who have already had one.

Most strokes are the kind this drug targets. The CDC puts about 87% of strokes in the ischemic category, meaning a clot or narrowed vessel blocks blood flow to part of the brain.

Standard care after an ischemic stroke already includes antiplatelet drugs such as aspirin or clopidogrel. Those stop platelets from clumping. Yet even on guideline treatment, recurrence stays stubborn, which is why researchers have spent years looking for something to add on top without turning a small stroke into a dangerous bleed.

How the New Stroke Prevention Pill Works

Blood clotting runs on a chain of proteins called clotting factors. Older anticoagulants, like warfarin or apixaban, block steps near the center of that chain. That makes them strong at preventing clots, and it is also why they raise bleeding risk: the same steps help seal a cut or a torn vessel.

Asundexian blocks a different link, factor XIa. The theory behind this drug class is that factor XIa matters more for clots that keep growing inside vessels than for the quick plug your body forms after an injury. If that theory holds, you could slow harmful clots while leaving normal wound sealing mostly intact.

That is the whole pitch. Not a stronger blood thinner, but a more selective one. The trial results suggest the idea works in this group of patients, with some limits covered below.

What the FDA actually approved

The FDA's announcement lays out the label in specific terms:

• Dose: one 50 mg tablet a day, taken together with antiplatelet therapy.
• Who: adults after a recent mild-to-moderate non-cardioembolic ischemic stroke, or a high-risk transient ischemic attack (TIA, often called a mini-stroke).
• Not for: stroke prevention in people with atrial fibrillation.
• Designations: the agency gave it Fast Track and Priority Review.

"Non-cardioembolic" means the clot did not come from the heart. That distinction matters for who can take it, so it gets its own section below.

What the OCEANIC-STROKE Trial Showed

The approval rests on one large trial, OCEANIC-STROKE, published in the New England Journal of Medicine in April and funded by Bayer. It enrolled 12,327 adults in 37 countries. Everyone had a stroke with an NIH Stroke Scale score of 15 or lower, or a high-risk TIA, and was randomized within 72 hours of symptoms starting.

Half got asundexian and half got a placebo, and both groups stayed on their antiplatelet drugs. Median follow-up was 567 days, a little over 18 months.

Here are the headline results, as reported in the trial publication and summarized by NeurologyLive and the American College of Cardiology:

• Ischemic stroke: 6.2% on asundexian versus 8.4% on placebo.
• Heart-related death, heart attack or stroke: 9.2% versus 11.1%.
• Major bleeding: 1.9% versus 1.7%, a gap that was not statistically significant.
• Any side effect: 69.3% versus 70.1%, essentially the same.

The most common side effect was diarrhea. TCTMD reported it in 3.4% of people on the drug versus 2.8% on placebo.

The fine print on bleeding

"No added bleeding" is the line you will see in headlines, and it is only half the picture. The FDA label says major bleeding increased in patients older than 75 and during the first 90 days of treatment. Bleeding in the stomach and gut was also more common than with placebo.

So the overall average hides two groups where the tradeoff is tighter. If you or your parent is over 75, that is the first thing to raise with the prescriber.

A Worked Example: What 26% Means for 1,000 People

A "26% reduction" sounds large. Absolute numbers tell you more about what it means for one person. Using the trial's event rates over its roughly 18-month follow-up, picture 1,000 people who just had a mild stroke:

• On antiplatelets alone: about 84 would have another ischemic stroke.
• On antiplatelets plus asundexian: about 62 would.
• Difference: about 22 strokes prevented per 1,000 people.
• Bleeding: about 19 major bleeds versus 17, so roughly 2 extra.

Flip that around and about 45 people need to take the drug for roughly a year and a half to prevent one stroke. For each of those 45, the most likely result is no visible difference at all. For the one, it may mean avoiding a stroke that takes away speech, walking or independence.

The cost side of the same math

TCTMD reports a list price of $748.50 for a 30-day supply. At list price, a year of treatment comes to roughly $9,000. Bayer says list price does not reflect what most health plans or patients pay, and some patients may qualify for free drug through the Bayer US Patient Assistance Foundation.

Cost will shape who actually gets it. Cheryl Bushnell, speaking to TCTMD, said price is "probably going to be the main limiting factor." Before you start, ask your pharmacy for the real copay under your plan, and whether prior authorization is needed. If you are budgeting for a costly new prescription, our breakdown of what GLP-1 drugs actually cost each month walks through how coverage rules and self-pay options change the number you pay.

Who Should Not Take It, or Should Ask First

The label rules out more people than the headlines suggest. Talk this list through with your doctor rather than deciding from an article.

• Atrial fibrillation. Asundexian is not approved for stroke prevention in AFib. People with AFib usually need a full anticoagulant, and swapping one for this drug could leave them underprotected. If you wear a watch with an ECG feature, our guide to which fitness tracker numbers are real explains what an AFib alert can and cannot tell you.
• Strokes that came from the heart. The approval covers non-cardioembolic strokes only.
• Moderate or severe liver disease. The FDA does not recommend it here.
• Certain other medicines. Drugs that are both P-gp and strong CYP3A4 inducers, such as the seizure drug carbamazepine, can weaken it.
• Upcoming surgery. It should be stopped at least 24 hours before elective surgery or an invasive procedure.
• Clot-busting treatment. It should be held for at least 24 hours after thrombolysis for an acute stroke.

One more point: do not stop or change your current stroke medicines on your own because a new option exists. Stopping antiplatelet therapy without a plan can raise your risk in the short term.

Questions to Bring to Your Next Appointment

If you or a family member had an ischemic stroke or TIA recently, these questions turn a vague "should I try the new pill?" into a decision you can actually weigh:

1. Was my stroke non-cardioembolic, and have I been checked for atrial fibrillation?
2. How high is my personal risk of a second stroke, given my blood pressure, diabetes, cholesterol and smoking history?
3. Given my age and any past stomach bleeding, how big is my bleeding risk on this drug, especially in the first three months?
4. Do any of my current medicines interact with it?
5. What will it cost me under my plan, and am I eligible for assistance?

Timing matters too. The trial started people within 72 hours of their stroke, so the evidence speaks most clearly to people early in recovery. If your stroke was years ago, ask whether the data apply to you at all.

And the basics still carry the most weight. Blood pressure control, cholesterol treatment and not smoking remain the foundation of secondary prevention. A new pill sits on top of that, not in place of it. If you are also weighing long-term medicines later in life, see what a new trial shows about stopping statins after 70, which covers a different group (people who never had a stroke) and why the answer differs.

Frequently Asked Questions

What is asundexian used for?

Asundexian (sold as Sunharbo) is a once-daily 50 mg pill approved by the FDA on November 9 to lower the risk of another stroke in adults after a recent mild-to-moderate non-cardioembolic ischemic stroke or high-risk TIA. It is taken together with antiplatelet drugs such as aspirin.

Is asundexian a blood thinner?

Yes, but a selective one. It blocks factor XIa, a clotting protein thought to matter more for harmful clot growth than for normal wound sealing. In the main trial, overall major bleeding was similar to placebo, though the FDA notes higher bleeding in people over 75 and in the first 90 days.

Can people with atrial fibrillation take asundexian?

No. The FDA did not approve it for stroke prevention in atrial fibrillation. People with AFib generally need a full anticoagulant, so ask your doctor before making any change.

How much does Sunharbo cost?

The reported list price is $748.50 for a 30-day supply, or roughly $9,000 a year. What you pay depends on your insurance, and Bayer says some patients may get it free through its patient assistance foundation.

Should I switch from aspirin to asundexian?

No. Asundexian is meant to be added to antiplatelet therapy, not to replace it. Never stop aspirin or clopidogrel on your own after a stroke. Discuss the new option with your neurologist or primary care doctor.

The Bottom Line

The new stroke prevention pill is a real step: a 26% relative cut in repeat ischemic strokes without a clear rise in major bleeding across the trial as a whole. In plain numbers, that is about 22 fewer strokes for every 1,000 people over a year and a half.

It is also narrow. It applies to people with a recent mild-to-moderate stroke or TIA that did not come from the heart, it is not for atrial fibrillation, and older adults face more bleeding early on. Price may be the biggest barrier of all.

If you or someone you care for had a recent stroke or TIA, bring this to your neurologist or primary care doctor at the next visit, with the questions above. And if anyone shows sudden face drooping, arm weakness or slurred speech, call 911 right away. No pill replaces fast emergency care.